• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Health Products Association - China Executive Director Reflects on Market Dynamics, Challenges

    Blood Sugar Management: Personalized Testing Drives Home The Need for Early Intervention

    New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance

    Tapping Functional Beverages to Meet Modern Wellness Needs

    Adaptogens: Where Ancient Remedies Meet Modern Wellness Products
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Pharmavite Expands in Ohio with $200 Million Investment

    Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company

    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products

    NOW Identifies Misleading Certificate of Analysis for Supplements Sold on Amazon

    Kensing Acquires Vitae Naturals
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Kensing Acquires Vitae Naturals

    Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast

    CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise

    Shiitake Mushroom Extract Appears Helpful in HPV Infections

    United Plant Savers Launches First Film Festival
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Pharmavite Expands in Ohio with $200 Million Investment

    Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company

    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products

    NOW Identifies Misleading Certificate of Analysis for Supplements Sold on Amazon

    Kensing Acquires Vitae Naturals
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products

    Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast

    CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise

    Shiitake Mushroom Extract Appears Helpful in HPV Infections

    Upcycled Coffeeberry® Cascara Offers Versatility in Functional Beverage Development
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Ecuadorian Rainforest

    Aiya America, Inc. (Aiya Matcha)

    Botanic Healthcare LLC

    Verdure Sciences

    ESHA Research
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Ecuadorian Rainforest

    Aiya America, Inc. (Aiya Matcha)

    Botanic Healthcare LLC

    Verdure Sciences

    ESHA Research
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Solid Dosage Outsourcing Trends

    Ease of manufacture, relative cost-effectiveness, and patient acceptance make oral solids the most common dosage form.

    Solid Dosage Outsourcing Trends
    Related CONTENT
    • Pharmaceutical Oral Solids Market Update
    • Oral Solids: Market & Technology Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • An Interview with Vishal Shah, Director of Nutriventia (a brand of Inventia Healthcare Limited)
    • Stepan Lipid Nutrition
    By Tim Wright, Editor, Contract Pharma03.01.18
    Oral solids continue to be the most common dosage form in the pharmaceutical market. They are cost-effective, easy to manufacture and patient-friendly. Advances in drug delivery technology, such as targeted drug delivery and sustained release dosage forms, are enabling oral solids to achieve even greater levels of bioavailability while reducing the frequency of drug administration.

    Other benefits exist, according to Justin Schroeder, executive director, marketing, business development and design, PCI Pharma Services, in terms of “relatively uncomplicated packaging needs and storage and distribution requirements due to chemical and physical stability.”

    Future Market Insights forecasts the global oral solid dosage pharmaceutical formulation market to grow from $493.2 billion in 2017 to $926.3 billion by 2027, representing a compound annual growth rate (CAGR) of 6.5%. According to IMS Health, nine of the top 10 drugs based on monthly prescription volume are oral solid doses and the top selling drug by sales figures is also an oral solid dose.

    “Growth in the oral solid dose outsourcing market remains strong despite the fact that competition continues to increase,” said Kimberly McClintock, executive vice president, Metrics Contract Services. She pointed out that external funding from venture capital sources has been very active, driving an increase in the number of early-phase development programs.

    Key Trends
    Although the market has seen the growth of biologics and small-molecules often delivered parenterally or via alternative routes, solid dosage products continue to dominate the existing pharmaceutical landscape while enjoying a healthy share of new product development. “However, while the growth of biologics in the marketplace is likely to hamper the growth of the oral solid dosage formulation market over time, the solid dose outsourcing market remains strong,” said Mr. Schroeder.

    Anil Kane, executive director, global head of technical and scientific affairs, Patheon, said he is seeing an increasing number of life cycle management strategies being executed. “Controlled release formulations to reduce the frequency of dosing and thereby improve patient compliance are on the rise,” he said. “Pediatric products continue to grow as well due to changes in regulatory requirements in this area and the opportunity of obtaining an exclusivity period.”

    Also discussing pediatric products, Mr. Schroeder said the adoption and 2012 reauthorization of the Best Pharmaceuticals for Children Act (BPCA) provides an incentive for drug companies to conduct FDA-requested pediatric studies by granting an additional six months of marketing exclusivity, as well as the Pediatric Research Equity Act (PREA), which requires drug companies to study their products in children under certain circumstances.

    “While some of these pediatric medicines are developed as traditional oral solid dose, drug companies may opt for powder delivery forms for the numerous benefits in delivery to this population,” he said. “With the proper formulation, these powder therapies can be utilized by parents by virtue of being mixed with water or juice as an oral suspension, or potentially mixed with palatable foods such as yogurt or apple sauce. Therefore, the market may experience an increase in powder for reconstitution development in an attempt to address this need.”

    In addition, fixed dose combinations (FDCs) offer a popular line extension opportunity to potentially achieve synergistic clinical effects of multiple active pharmaceutical ingredients (APIs) in a pill while reducing the pill burden on patients.

    Mr. Kane also said the market is seeing off patent drugs being evaluated for potential benefits in completely new indications. “Shelved molecules are resurfacing,” he said. “New chemical entities that were evaluated in preclinical toxicology and found safe but did not meet early candidate selection criteria due to priority reasons and were shelved, are now being re-evaluated.”

    A key trend, according to Ms. McClintock, is the use of co-processed and multi-functional excipients, which scientists can utilize to speed up the formulation development process for oral solid dosage products. She also said the commercial manufacture of smaller batch sizes is affecting both pharmaceutical companies and contract service providers.

    “Oncology medications are not your traditional large production volume products and never will be,” she said. “This poses a challenge to both sides: How does the pharmaceutical company find a commercial manufacturer suitably structured to economically deliver a low-volume product, and how does the commercial manufacturing organization price such work to remain profitable? Both sides must work together to find a solution that benefits the parties involved.”

    At PCI, Mr. Schroeder said the company has seen a shift in development projects toward more complex potent molecules, driven primarily by oncological products. “Manufacturing of solid dosage forms itself requires a range of processing technologies, and a real understanding of the product and how it behaves during processing,” he said. “The more specific the action, the more potent the molecule. The more potent the molecule, the more complex the therapy, and the more complex the therapy, the more complex the processing requirements.

    “Further still, the more complex the processing requirements, the more complex the formulation optimization. The Quality by Design (QbD) approach to development has led to a better understanding of the variables that influence product development and this is of particular importance when processing highly potent molecules. This has led to a real need within the marketplace for contract development and manufacturing organizations (CDMOs) being able to offer a more specialist service for the development and manufacturing of such molecules.”

    Growth Opportunities
    While there continues to be a need for expanding capabilities for specialized dosage forms such as modified-release, pediatric-geriatric, and abuse-deterrent formulations, another growth opportunity for CDMOs, according to Ms. McClintock, is to expand integrated offerings by adding services such as clinical packaging and distribution. “Continuous processing is also becoming a more widely accepted practice, especially with large pharma and biotech clients. However, this also can prove to be a challenge for a CDMO since it requires large upfront costs, making it difficult to pull the trigger for investment.”

    Mr. Schroeder reiterated that the opportunities for growth in solid dose formulations lie in the potent arena, primarily driven by oncological products, but also in other treatment areas including those used for pain relief and for treatments relating to the central nervous system (CNS).

    “With over 200 cancers identified, the market shows no sign of slowing in terms of the pace of development, especially for some of the more rare cancer types whereby FDA fast track to designated orphan/ultra-orphan status is possible,” he said. “By the same token, the market growth in biologics and non-solid dose formulations is also increasing and as a result, CDMOs will need to diversify to meet this demand.” 

    For Patheon’s Mr. Kane, it’s the new phase of digital health and digitized drug products and technologies based on digitization and electronic tagging that will be of interest in the next several years and could revolutionize the industry.

    “There is a lot of literature to show that drugs are not effective because patients do not adhere to the prescribing instructions. They do not take the right dose at the right frequency of administration,” he said. “Ingestible sensors in drug products that can monitor drug intake along with measurement of biometrics that sends this data to a physician or service provider through a wireless network promises to improve patient adherence and ultimately healthcare. The individual sensors have a unique identification code of the product, lot number, manufacturing details; and this data will also ensure the right medication is taken by the patient and will avoid counterfeit drug products in the market.

    “These technology-enabled approaches give pharmaceutical companies the power to scan a pill found anywhere in the world and immediately confirm its authenticity, place and date of manufacture, lot number, and other product intelligence directly from the dosage form itself, without ever needing the product packaging,” he said. “According to a CNN report, between 100,000 and one million people die each year from counterfeit drugs. Contract developers and commercial manufacturers could have a big role to play in advancing these technologies for clinical or commercial drug products by partnering with technology developers and sponsor companies.” 

    Customer Expectations
    Customer expectations for aggressive early-phase timelines continue to grow as the U.S. Food and Drug Administration (FDA) has granted more than 400 orphan designations annually within the past several years, according to Ms. McClintock. “Customer expectations for high-quality scientific expertise and value-priced services remain steady,” she said. “At the same time, they also expect a higher degree of flexibility from CDMOs. In the development space, clients are looking for a collaborative relationship with their CDMOs. This is not a new or evolving trend, but one that becomes more demanding each year. CDMOs must determine the right balance between utilization of resources in collaboration activities, versus delivery of milestones expected by clients. Investments made in project management and support functions will help, but CDMOs still often face difficult decisions to keep clients happy.”

    Another key driver, she said, is the ability of CDMOs to meet the increased demands of shorter timelines. “Clients, their investors, and their patients all want to see new products entering clinical trials and, subsequently, the market more quickly,” she said. “While this demand remains constant, CDMOs must continue to maintain a high level of quality standards within a regulated industry. This driver has CDMOs evaluating internal systems, processes and procedures to become as efficient as possible to help clients meet their milestones.”

    Customer expectations are very high and it is important to remember that often the molecules in question are very expensive and in short supply, and therefore development programs are required that maximize outputs while minimizing wastage, according to Mr. Schroeder. “Traditional early stage development can prove troublesome due to the time and cost involved in the formulation and analytical development, and so new and novel technologies should be assessed,” he said.

    One such technology available would be Xcelodose micro-dosing, a system providing drug in capsule (DIC) capabilities. “At the early stages of development, such a system reduces the time and cost involved in traditional development by putting API directly into capsules and in turn, delivering drugs into patients earlier within the cycle,” said Mr. Schroeder. “This approach can reduce time, costs, and wastage and provide a faster ‘yes’ decision in terms of further development and equally the ‘fail and fail fast’ should a molecule show no therapeutic benefit. Again, the identification of a CDMO able to offer diversity in their approach to early stage development could be of interest to a pharmaceutical company.”  
    Related Searches
    • Analytical
    • Health
    • Cancer
    • Delivery
    Related Knowledge Center
    • Contract Manufacturing
    • Delivery & Dosage Technologies
    Suggested For You
    Pharmaceutical Oral Solids Market Update Pharmaceutical Oral Solids Market Update
    Pharmaceutical Manufacturing Equipment Trends Pharmaceutical Manufacturing Equipment Trends
    Oral Solids: Market & Technology Trends Oral Solids: Market & Technology Trends
    An Interview with Vishal Shah, Director of Nutriventia (a brand of Inventia Healthcare Limited) An Interview with Vishal Shah, Director of Nutriventia (a brand of Inventia Healthcare Limited)
    Stepan Lipid Nutrition Stepan Lipid Nutrition
    Pharma/Biopharma Manufacturing & Packaging Equipment Trends Pharma/Biopharma Manufacturing & Packaging Equipment Trends
    FDA Recalls and Destroys Kratom Products FDA Recalls and Destroys Kratom Products
    Ready-To-Drink Coffee Consumption Reaches 5.5 Billion Liters Ready-To-Drink Coffee Consumption Reaches 5.5 Billion Liters
    Refreshing Ideas for Healthy Snacks & Nutrition Bars Refreshing Ideas for Healthy Snacks & Nutrition Bars
    Licensing & Partner-Finding in the Food Industry Licensing & Partner-Finding in the Food Industry
    Hampton Creek Launches Just Scramble, Announces Funding, & Sustainability Metrics Hampton Creek Launches Just Scramble, Announces Funding, & Sustainability Metrics
    Nellson Nutraceutical to Acquire Genysis Brand Solutions Nellson Nutraceutical to Acquire Genysis Brand Solutions
    FDA Unveils Draft Guidance on Best Practices for Convening a GRAS Panel FDA Unveils Draft Guidance on Best Practices for Convening a GRAS Panel
    FDA Warns Against SARMs in Body-Building Products FDA Warns Against SARMs in Body-Building Products
    AHPA Publishes Guidance on Foreign Matter Limits in Herbal Ingredients AHPA Publishes Guidance on Foreign Matter Limits in Herbal Ingredients

    Related Features

    • Contract Manufacturing | Delivery & Dosage Technologies
      Pharmaceutical Oral Solids Market Update

      Pharmaceutical Oral Solids Market Update

      Pharmaceutical CDMOs continue to invest in oral solid dose development and manufacturing capabilities.
      By Tim Wright, Editor, Contract Pharma 03.02.22

    • Contract Manufacturing | Delivery & Dosage Technologies
      Oral Solids: Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      By Tim Wright, Editor, Contract Pharma 03.03.21

    • Contract Manufacturing | Medical Nutrition
      Pharmaceutical Manufacturing Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      By Kristin Brooks, Managing Editor, Contract Pharma 03.03.21


    • Delivery & Dosage Technologies | Dietary Supplements | Healthcare Trends | Herbs & Botanicals | Vitamins
      An Interview with Vishal Shah, Director of Nutriventia (a brand of Inventia Healthcare Limited)

      An Interview with Vishal Shah, Director of Nutriventia (a brand of Inventia Healthcare Limited)

      Shah is passionate about solving ingredient problems by applying technology platforms that make it easier to deliver and enhance natural products.
      By Sheldon Baker 10.01.20

    • Stepan Lipid Nutrition

      Stepan Lipid Nutrition

      ...
      Melissa DeVincenzo, Marketing Consultant 10.31.18

    Loading, Please Wait..
    Trending
    • Three Grams Of Omega-3s May Be Optimal Dose For Reducing Blood Pressure
    • 3 grams of Omega-3s May be Optimal Dose for Reducing Blood Pressu
    • High Blood DHA Levels Linked To 49% Reduced Risk Of Alzheimer’s
    • CoQ10 And Royal Jelly Supplementation May Improve High Intensity Exercise
    Breaking News
    • Pharmavite Expands in Ohio with $200 Million Investment
    • Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company
    • Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products
    • NOW Identifies Misleading Certificate of Analysis for Supplements Sold on Amazon
    • Kensing Acquires Vitae Naturals
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • Tapping Functional Beverages to Meet Modern Wellness Needs
    • Adaptogens: Where Ancient Remedies Meet Modern Wellness Products
    • New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance
    • Health Products Association - China Executive Director Reflects on Market Dynamics, Challenges
    • Blood Sugar Management: Personalized Testing Drives Home The Need for Early Intervention
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Pharmavite Expands in Ohio with $200 Million Investment
    Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company
    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products
    Coatings World

    Latest Breaking News From Coatings World

    Clariant’s Launches Dispersogen Flex 100
    Lincoln Tech Enters Partnership with AkzoNobel
    AkzoNobel Launches International Interzone 945GF
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    ENDRA Life Sciences Issued 27th Patent
    AI-Enabled SKOUT Device Improves Colorectal Cancer Screening
    Simon Johnson Appointed as Senior Business Development VP at MedAcuity
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Takeda to Expand U.S. Footprint
    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines
    WuXi STA Opens High-Potency API Plant
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Latest Updates About Cosmoprof North America
    Meet the Clean Beauty Brand for Dogs
    Paco Rabanne Introduces Elle Fanning as Ambassador for New ‘Fame’ Fragrance
    Happi

    Latest Breaking News From Happi

    Two-Part Skincare Product Patented by Estée Lauder Companies
    American Cleaning Institute Pens Letter to Congress Encouraging Examination of Recyclability Improvements
    The Expert Panel for Fragrance Safety Celebrates 55 Years
    Ink World

    Latest Breaking News From Ink World

    INX Launches INXFlex Contour for Shrink Sleeve Market
    Xerox Announces Unexpected Passing of Vice Chairman and CEO John Visentin
    MNYPIA Golf Outing Set to Tee Off on Aug. 17
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Meyers purchased by third generation of Dillon family
    Epson now shipping ColorWorks C4000 inkjet label printer
    Nobelus launches new films for prime labels
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    What You’re Reading on Nonwovens-Industry.com
    Daio, Livedo Partner to Recycle Diapers
    Suominen Launches Hydraspun Reserve
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    3D Systems and EMS-GRILTECH Enter Strategic Partnership
    AIP Researchers Develop Microfluidic-Based Soft Robotic Prosthetic
    David Sharp Named Global Marketing VP at Catalyst OrthoScience
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Impinj Launches E910 RFID Reader Chip for Next Generation Enterprise IoT
    onsemi Receives Recognition for Sustainability for Third Straight Year
    Xerox Announces the Unexpected Passing of Vice Chairman and CEO John Visentin

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login